idelalisib (zydelig) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Fast Track FDA Accelerated Approval FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Idelalisib is a first-in-class selective inhibitor of adenosine-5'-triphosphate (ATP) binding to PI3Kdelta kinase, resulting in inhibition of the P13K signalling pathway in malignant B cells. The compound is approved for the treatment of several types of blood cancer. Idelalisib is intended to be used in combination with rituximab as second or subsequent line therapy for the treatment of chronic lymphocytic leukaemia. The drug may cause fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.   NCATS

Chemistry

  • SMILES: CC[C@H](NC1=NC=NC2=C1N=CN2)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4
  • InChIKey: IFSDAJWBUCMOAH-HNNXBMFYSA-N
  • Mol. Mass: 415.423
  • ALogP: 3.75
  • ChEMBL Molecule:
    idelalisib  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$68.1216

United States

$124.0388
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5-fluoro-3-phenyl-2-[(1s)-1-(3h-purin-6-ylamino)propyl]quinazolin-4(3h)-one | 5-fluoro-3-phenyl-2-((s)-1-(9h-purin-6-ylamino)-propyl)-3h-quinazolin-4-one | cal101 | cal 101 | cal-101 | gs-1101 | gs-11cal-101 | idelalisib | idelaslisib | zydelig

Organizations (39)

Research & Development (39)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (38)

Approved Indications (3)


 

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Follicular (approved 2014)

Lymphoma, Non-Hodgkin

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Amyloidosis (Phase 2)

Anemia (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 2)

Hodgkin Disease (Phase 2)

Immunoglobulin Light-chain Amyloidosis (Phase 2)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell ()

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Prolymphocytic (Phase 2)

Lymphoma (Phase 4)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin ()

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasm Metastasis (Phase 1/Phase 2)

Neoplasms ()

Pancreatic Neoplasms (Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Primary Myelofibrosis (Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Recurrence (Phase 1/Phase 2)

Rhinitis, Allergic (Phase 1)

Squamous Intraepithelial Lesions (Phase 1)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 58
  • # of Trial Organizations: 39

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue